| Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data J Ochalek, J Lomas, K Claxton BMJ Global Health 3 (6), 2018 | 292* | 2018 |
| A health opportunity cost threshold for cost-effectiveness analysis in the United States DJ Vanness, J Lomas, H Ahn Annals of internal medicine 174 (1), 25-32, 2021 | 131 | 2021 |
| Resolving the “cost-effective but unaffordable” paradox: estimating the health opportunity costs of nonmarginal budget impacts J Lomas, K Claxton, S Martin, M Soares Value in Health 21 (3), 266-275, 2018 | 87 | 2018 |
| Cost per DALY averted thresholds for low-and middle-income countries: evidence from cross country data JM Ochalek, J Lomas, KP Claxton Centre for Health Economics, University of York, 2015 | 83 | 2015 |
| Healthcare cost regressions: going beyond the mean to estimate the full distribution AM Jones, J Lomas, N Rice Health economics 24 (9), 1192-1212, 2015 | 73 | 2015 |
| Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach J Ochalek, H Wang, Y Gu, J Lomas, H Cutler, C Jin Pharmacoeconomics 38 (12), 1319-1331, 2020 | 55 | 2020 |
| Estimating the marginal productivity of the English National Health Service from 2003 to 2012 J Lomas, S Martin, K Claxton Value in Health 22 (9), 995-1002, 2019 | 54 | 2019 |
| Applying beta‐type size distributions to healthcare cost regressions AM Jones, J Lomas, N Rice Journal of Applied Econometrics 29 (4), 649-670, 2014 | 48 | 2014 |
| An educational review about using cost data for the purpose of cost-effectiveness analysis M Franklin, J Lomas, S Walker, T Young Pharmacoeconomics 37 (5), 631-643, 2019 | 45 | 2019 |
| Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity S Martin, J Lomas, K Claxton BMJ open 10 (10), e036411, 2020 | 44 | 2020 |
| The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all‐cause and disease specific models of mortality K Claxton, J Lomas, S Martin Health economics 27 (6), 1017-1023, 2018 | 38 | 2018 |
| A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs AM Jones, J Lomas, PT Moore, N Rice Journal of the Royal Statistical Society Series A: Statistics in Society 179 …, 2016 | 34 | 2016 |
| Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment JRS Lomas Value in Health 22 (8), 898-905, 2019 | 33 | 2019 |
| Accounting for timing when assessing health-related policies K Claxton, M Asaria, C Chansa, J Jamison, J Lomas, J Ochalek, ... Journal of Benefit-Cost Analysis 10 (S1), 73-105, 2019 | 26 | 2019 |
| Empirical estimates of the marginal cost of health produced by a healthcare system: methodological considerations from country-level estimates LC Edney, J Lomas, J Karnon, L Vallejo-Torres, N Stadhouders, ... Pharmacoeconomics 40 (1), 31-43, 2022 | 25 | 2022 |
| Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014 S Martin, F Longo, J Lomas, K Claxton BMJ open 11 (10), e046417, 2021 | 25 | 2021 |
| Reflecting the health opportunity costs of funding decisions within value frameworks: initial estimates and the need for further research J Ochalek, J Lomas Clinical Therapeutics 42 (1), 44-59. e2, 2020 | 20 | 2020 |
| Valuing health outcomes: developing better defaults based on health opportunity costs J Ochalek, K Claxton, J Lomas, KM Thompson Expert Review of Pharmacoeconomics & Outcomes Research 21 (4), 729-736, 2021 | 19 | 2021 |
| Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries J Ochalek, K Abbas, K Claxton, M Jit, J Lomas BMJ global health 5 (10), e003006, 2020 | 19 | 2020 |
| How effective is marginal healthcare expenditure? New evidence from England for 2003/04 to 2012/13 S Martin, J Lomas, K Claxton, F Longo Applied Health Economics and Health Policy 19, 885-903, 2021 | 18 | 2021 |
